7-OH Lawsuits Mount as DEA Classifies Synthetic Kratom Compounds as Schedule I

Why it matters

The scheduling action and parallel litigation highlight growing legal and regulatory scrutiny of concentrated 7-OH products, which plaintiffs say are far more dangerous than traditional kratom leaf but have been marketed similarly.

The big picture

Kratom's market has shifted in recent years from basic leaf-based powders and teas toward concentrated extracts and shots with much higher levels of 7-hydroxymitragynine, a compound that occurs only in trace amounts naturally. That shift has fueled both a DEA emergency scheduling action and a growing wave of product liability lawsuits.

Key findings

• The DOJ announced Aug. 25 that the DEA is temporarily placing mitragynine pseudoindoxyl (MGPI), MGM-15 and MGM-16 into Schedule I, the most restrictive federal drug category.
• The three compounds are described by regulators as potent mu-opioid receptor agonists raising concerns about dependence and respiratory depression.
• The American Kratom Association filed a lawsuit against the DEA on Aug. 26 seeking to prevent the scheduling order from being applied to traditional kratom containing only trace, naturally occurring amounts of MGPI.
• Separate product liability lawsuits allege 7-OH products can be up to 10 times more potent than morphine, with manufacturers accused of failing to warn consumers of addiction and cardiac risks.
• The Schedule I designation applies only to the three named synthetic compounds, not to traditional botanical kratom or naturally occurring 7-OH.

What they say

"The emergency scheduling action subjects the manufacture, distribution and possession of these substances to the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances," the U.S. Department of Justice said in its announcement.

Bottom line

**Federal scheduling of three synthetic kratom-derived opioids is running in parallel with a growing wave of lawsuits against 7-OH product makers, both driven by concerns that concentrated derivatives pose risks distinct from traditional kratom leaf.**